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Abstract: Renal tumors comprise approximately 7% of all malignant pediatric tumors. This is a
highly heterogeneous group of tumors, each with its own therapeutic management, outcome, and
association with germline predispositions. Histopathology is the key in establishing the correct
diagnosis, and therefore pathologists with expertise in pediatric oncology are needed for dealing with
these rare tumors. While each tumor shows different histologic features, they do have considerable
overlap in cell type and histologic pattern, making the diagnosis difficult to establish, if based
on routine histology alone. To this end, ancillary techniques, such as immunohistochemistry and
molecular analysis, can be of great importance for the correct diagnosis, resulting in appropriate
treatment. To use ancillary techniques cost-effectively, we propose a pattern-based approach and
provide recommendations to aid in deciding which panel of antibodies, supplemented by molecular
characterization of a subset of genes, are required.
Keywords: pediatric; oncology; renal tumors; immunohistochemistry; molecular analysis
1. Introduction
In Europe, each year about 1000 children are diagnosed with a renal tumor, thereby comprising
approximately 7% of all pediatric malignant tumors. Approximately 90% of pediatric renal tumors
comprise Wilms tumor (WT), the remainder consisting of clear cell sarcoma of the kidney (CCSK),
malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic
nephroma (CMN), and other rare tumors (Table 1) [1]. They represent a very heterogeneous group,
which includes a spectrum of tumors from those with low malignant potential (e.g., CMN) to
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highly aggressive tumors (e.g., MRTK) [2,3], requiring different treatment, and showing remarkable
intra-tumor histologic and genetic heterogeneity [4,5]. In addition, it has been recognized that an
increasing number of pediatric renal tumors have been associated with specific syndromes or diseases
(Table S1) [6], which highlights the importance of precise tumor diagnosis, not only for appropriate
treatment, but also for genetic counseling.
Table 1. Distribution of pediatric renal tumors in children <15 year of age according to the National
Registry Childhood Tumors (UK).







WT = Wilms tumor; CCSK = clear cell sarcoma of the kidney; MRTK = malignant rhabdoid tumor of the kidney;
CMN = congenital mesoblastic nephroma; RCC = renal cell carcinoma.
While imaging techniques are continuously improving, they are still unable to reliably diagnose and
distinguish the most relevant pathology based risk groups, although some new techniques (like MRI-Diffusion
Weighted Imaging) might be helpful in the near future [7]. The clinical characteristics of children with renal
tumors are similar, although some (like age distribution) may be helpful in the differential diagnosis [8].
In nearly all tumors, the final diagnosis and classification of clinically relevant (sub)types still
relies on histopathologic examination. Updated pathology guidelines for handling renal tumors have
been published recently by the Renal Tumor Study Group of the International Society of Paediatric
Oncology/Société Internationale D’Oncologie Pédiatrique (SIOP-RTSG) in the SIOP-RTSG UMBRELLA
2016 protocol [9]. These guidelines recommend that tumors should be extensively sampled, to allow
diagnostic classification, staging, and to capture tumor heterogeneity [9]. Difficulties in achieving the
correct histologic classification may arise due to the ability of tumors to display a variety of overlapping
histologic patterns. This stresses the need for adequate tumor sampling, since it can reveal other
important histopathologic clues. Biopsies, performed in selected cases only, might pose even more
difficulties, due to the limited availability of material [10]. Finally, in some cases where abdominal tumors
are so large that the kidney and adjacent organs are unrecognizable, even non-renal tumors have to be
included into the differential diagnosis. In many cases, additional ancillary techniques are needed to
establish the final diagnosis. Since clinically relevant discrepancies between the diagnosis and/or staging
of institutional pathologists and central pathology review persist [11,12], rapid central pathology review
is now mandatory in both the Children’s Oncology Group (COG) and SIOP studies, in order to establish
the correct diagnosis and stage within a clinically relevant timeframe and start appropriate treatment.
In this review, to aid in the diagnostic process, we use a pattern-based diagnostic approach for
the most common pediatric renal tumors, by discussing pattern-based differential diagnoses and in
providing recommendations for the use of ancillary techniques.
2. A Pattern-Based Approach to the Use of Ancillary Techniques in Pediatric Renal Tumors
In general, there are three major histologic patterns which are the basis for the differential diagnoses
of any tumor, including pediatric renal tumors: an epithelial, a mesenchymal, and an undifferentiated
pattern (Tables 2–4). Most tumors harbor histological clues to the diagnosis, although these can be
present only focally. In WTs, all three patterns are often present, but many WTs show only one or
two patterns (Figures 1–3), or show the other patterns only focally. This underlines the reasons why
extensive sampling is required, in order to capture all tumor features [9]. The most common pediatric
renal tumors have been described and reviewed extensively elsewhere [3,13–16], so we only briefly
recapitulated their main histologic features (Table S2). Since some tumors harbor a variety of histologic
patterns, they appear in more than one of these categories.
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WT1 (n) AMACR Pankeratin CK7 TFE3 TFEB MelanocyticMarkers
BRAF
V600E
WT ++ −− +/− −− −− −− −− −− [16–25]
NR + NA + −/+ * NA NA NA − [17,18]
MA ++ − +/− −/+ * NA NA NA + [17,18,20–22,25,26]
Xp11.2 tRCC −− ++ −/+ * − ++ −− −/+ −− [14,24,26–30]
t(6;11) RCC −− + − − −− + + −− [14,24,26–30]
PRCC −− ++ ++ + −− −− −− −− [17,20,21,26–28]
WT = Wilms tumor; NR = nephrogenic rest; MA = metanephric adenoma; RCC = renal cell carcinoma;
tRCC = translocation associated RCC; PRCC = papillary RCC; n = nuclear; NA = not available; * = if positive, often
only focally; scoring: ++ >95% positive cases; + 76–95% positive cases; +/− 51–75% positive cases; −/+ 26–50%
positive cases; − 5–25% positive cases; −− <5% positive cases.






WT1 (n) NGFR BCOR CyclinD1 INI1 CD34 BCL-2
WT +/− − −/+ * − ++ −/+ + Rhabdomyoblasticcells desmin + [16,23,31–37]
CCSK −− ++ + ++ ++ −− −/+ [16,31–39]
Cellular/Mixed
CMN −− − * − * +/++ ++ −− −− [16,19,31–37,40,41]
Classic CMN −− −− − * +/++ ++ −− −− [16,19,31,34–37,40,41]
MST +/− − − * NA ++ ++ NA BRAFV600E
+/−
[33,34,42,43]
WT = Wilms tumor; CCSK = clear cell sarcoma of the kidney; CMN = congenital mesoblastic nephroma;
MST = metanephric stromal tumor; n = nuclear; c = cytoplasmic; var = variable; m = membranous staining;
NA = not available; * = if positive, often only focally. Scoring: ++ >95% positive cases; + 76–95% positive cases; +/−
51–75% positive cases; −/+ 26–50% positive cases; − 5–25% positive cases; −− <5% positive cases.







(n) INI1 NGFR Keratin CD99 NE Desmin PAX8 NB84
Cyclin
D1
WT + a ++ - +/− − −− − ++ −− − [16,17,23,31,34,36,40,44–51]
MRTK −(c +/−) −− − *
+/− (d)
* +/− NA +/−
c
−− NA ++ [15,16,31,34,36,40,46–48,52]






DSRCT + b ++ −− + (d) − − ++ (d) −− − −/+
[16,34,36,40,44,
47,48,50,51]
EWS −− ++ − − ** ++ (m) − −− −− −/+ ++ Fli1+ in
>85% [16,36,45,47–51]
WT = Wilms Tumor; MRTK = malignant rhabdoid tumor of the kidney; NB = neuroblastoma; DSRCT = desmoplastic
small round cell tumor; EWS = Ewing sarcoma; n = nuclear; NE markers = neuroendocrine markers; m = membranous
staining; d = dotlike paranuclear staining; c = cytoplasmic; a = both N-terminal and C-terminal clone; b = C-terminal
clone only; if positive, often only focally; * rarely diffuse positive staining; scoring: ++ >95% positive cases; + 76–95%
positive cases; +/− 51–75% positive cases; −/+ 26–50% positive cases; − 5–25% positive cases; −− <5% positive cases.
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2.1. Epithelial Pattern
2.1.1. Histology
Tumors demonstrating a pure epithelial pattern include epithelial type WT, hyperplastic perilobar
nephrogenic rests, RCC and metanephric adenoma (MA), with WT being by far the most common one.
Epithelial WTs (Figure 1) usually occur in younger children (median age 15 months), and about
80% of cases are stage I [54]. The tumor consists of epithelial structures, which may demonstrate
the whole spectrum of nephrogenesis, varying from poorly and moderately differentiated to mature
tubules and glomeruli-like structures. Tumor cells are often columnar with elongated, hyperchromatic
and crowded nuclei, inconspicuous nucleoli, and scant cytoplasm. Mitoses are often easily identified.
For WTs that consist entirely of poorly and moderately differentiated tubules, the diagnosis is more
difficult, and tumors, such as papillary RCC and MA, have to be excluded.
If nephrogenic rests (NRs) are identified, the diagnosis of WT can be reliably established since
NRs are virtually never associated with non-WTs [55]. NRs are foci of embryonal cells that persist
after 36 weeks of gestation and they are considered precursors of WTs [56]. NRs accompany WTs in
approximately 40% in unilateral WTs and in >90% of bilateral WTs [56,57]. NRs are subdivided into
two main subtypes: perilobar nephrogenic rests (PLNRs) and intralobar nephrogenic rests (ILNRs).
PLNRs are confined to the periphery of the renal lobe, while ILNRs can be found anywhere within
the renal lobe [56,58]. Nephroblastomatosis is defined as the “diffuse or multifocal presence of
NRs” [56]. Hyperplastic NRs can be difficult to distinguish from WTs, as there are no histologic,
immunohistochemical or molecular features that are helpful, so the diagnosis is commonly based
on experts’ consensus. The presence of a fibrous capsule between the lesion and renal parenchyma
may be helpful in diagnosing a WT in patients treated with primary surgery, but not in those treated
with preoperative chemotherapy, where a pseudocapsule is often found around NRs (GMV, personal
observation).
RCC is the most important tumor in the differential diagnosis of epithelial WT, particularly in
older children [27]. Overall, RCCs account for only ~2–4% of pediatric renal tumors, but this increases
to >50% in children older than 12 years [27]. The most prevalent RCC types in adulthood (e.g., clear
cell RCC, papillary RCC) are less common in childhood [27], but it is papillary RCC (PRCC) which
needs to be considered in children in the differential diagnosis of epithelial WTs, due to the overlapping
histologic architecture and cell type. PRCCs can be separated into Type 1 and Type 2. Type 1 is
composed of small cuboidal cells with scant pale cytoplasm arranged as single layers on papillae,
tubules and glomerulus-like structures, and often contain foamy macrophages and psammoma bodies,
in contrast to WTs. Type 2 PRCCs show papillae lined with pseudostratified cells, abundant eosinophilic
to occasionally clear cytoplasm, and atypical nuclei with prominent nucleoli, which is not a common
feature in WT. PRCCs usually have no pseudocapsule, and lack a blastemal and stromal component.
In children, the Microphtalmia-associated Transcription factor family translocation RCC (MiT-RCC)
is the most common RCC subtype (42% of all pediatric RCCs), comprised of Xp11.2 tRCC (~90% of
cases) and t(6;11) RCC [27]. Since these tumors have distinct histologic characteristics (Table S2), they
are usually not difficult to diagnose and distinguish from WT, but the characteristic features can be
present only focally, and may thus, be easily overlooked [14].
In addition, there are some RCC subtypes, which are generally rare, with very few cases reported
in children. Still, they are important to recognize, since some of them are associated with germline
mutations or syndromes, including Anaplastic Lymphoma Kinase (ALK)-rearranged-RCC (ALK-RCC),
Succinate Dehydrogenase-deficient renal cell carcinomas (SDH-RCC), and Hereditary Leiomyomatosis
and Renal Cell Carcinoma-RCC (HLRCC-RCC) [59]. Most of these tumors show characteristic
histologic features (Table S2), although these can be present only focally, and immunohistochemistry
and molecular analysis will aid in establishing the correct diagnosis.
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Figure 1. The most common pediatric renal tumors with an epithelial pattern and their most 
important immunohistochemical staining. Epithelial Wilms tumor (WT) showing epithelial structures 
which shows characteristic strong nuclear staining for WT1 as well as lack of staining for CK7. The 
classical histology of metanephric adenoma (MA) consists of closely packed mature tubules and 
papillary structures as well as psammoma calcifications, which shows strong nuclear staining for 
WT1, but also strong staining for BRAFV600E corresponding to the BRAF mutation present in ~80–
90% of MAs. Xp11.2 translocation renal cell carcinomas (tRCCs) typically show large epithelioid cells 
with copious amounts of eosinophilic cytoplasm and a large eosinophilic nucleolus; these tumors 
show nuclear TFE3 staining and most cases show absent or decreased staining for cytokeratins, such 
as the negative cytokeratin 7 (CK7) shown here. Papillary renal cell carcinoma (PRCC) with typical 
papillary structures, often with rather small monotonous nuclei, with lack of reactivity to WT1, but 
strong staining for CK7. H&E and immunohistochemical stainings at 10× magnification; inset at 40× 
magnification.  
Metanephric adenoma is another tumor which can be difficult to distinguish from WTs and 
RCCs, especially in older children. Histologically, MAs consist of small, uniform closely packed 
tubules and papilla (Figure 1). Features which can aid in distinguishing them from WTs are the 
absence of a pseudocapsule, sharp demarcation from the renal parenchyma, the presence of small 
Figure 1. The most common pediatric renal tumors with an epithelial pattern and their most important
immunohistochemical staining. Epithelial Wilms tumor (WT) showing epithelial structures which
shows characteristic strong nuclear staining for WT1 as well as lack of staining for CK7. The classical
histology of metanephric adenoma (MA) consists of closely packed mature tubules and papillary
structures as well as psammoma calcifications, which shows strong nuclear staining for WT1, but
also strong staining for BRAFV600E corresponding to the BRAF mutation present in ~80–90% of MAs.
Xp11.2 translocation renal cell carcinomas (tRCCs) typically show large epithelioid cells with copious
amounts of eosinophilic cytoplasm and a large eosinophilic nucleolus; these tumors show n clear
TFE3 staining and most cases show absent or decreased staining for cytokeratins, such as the egative
cytokeratin 7 (CK7) shown here. Papillary renal cell carcinoma (PRCC) with typical papillary structures,
often with rather small monotonous nuclei, with lack of reactivity to WT1, but strong staining for CK7.
H&E and immunohistochemic l stainings at 10×magnificatio ; in et at 40×magnification.
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Metanephric adenoma is another tumor which can be difficult to distinguish from WTs and RCCs,
especially in older children. Histologically, MAs consist of small, uniform closely packed tubules
and papilla (Figure 1). Features which can aid in distinguishing them from WTs are the absence of a
pseudocapsule, sharp demarcation from the renal parenchyma, the presence of small uniform cells
with scant cytoplasm, bland nuclei, fine chromatin, absence of atypia, psammoma bodies, and rare
mitoses (in epithelial WTs mitoses are more common) [17,60]. Nevertheless, in a recent report, tumors
with histologic and molecular overlap between MA and epithelial WTs were described [61].
Other types of RCC that are more common in adulthood and rare in children are extensively
described in literature and not further described here [62–65]. Finally, in addition to tumors that are
genuinely epithelial, there are tumors that can have an epithelioid appearance, such as MRTKs, CCSKs
(see below), and epithelioid angiomyolipoma. However, these tumors have other features (such as fat
and/or aberrant vessels in epithelioid angiomyolipomas), which distinguish them from tumors with a
genuine epithelial pattern.
2.1.2. Immunohistochemistry
Immunohistochemistry using a small panel of immunohistochemical markers (Table 2) including
WT1, pan-cytokeratin (pan-CK), and CK7 is helpful in reaching a definite diagnosis in most cases.
Nevertheless, immunohistochemistry does not reliably differentiate between NRs and WTs.
In pure epithelial WTs, WT1 is positive in 80–90% of WTs, while all RCC types are negative for
WT1 [19,40]. Translocation RCCs are often only weakly positive for keratins, but strongly positive for
melanocytic markers (TFEB-tRCCs more commonly and more diffusely than TFE3-tRCCs). Xp11.2 RCC
and t(6;11) RCCs show nuclear TFE3 (Figure 1), and TFEB positivity, respectively [14,66]. Notably, a
diagnostic pitfall in TFE3 positive RCCs, is that the rare ALK-RCCs also stain positive [67]. Depending
on the RCC subtype, further immunohistochemical stains (e.g., CK7, AMACR, CD10, vimentin,
cathepsin K) will help establish the diagnosis and rule out WT [20,22,29,68].
If both WT1 and pan-CK are positive, the main differential diagnosis remains between epithelial
WT and MA. The majority (~90%) of MAs carry a BRAF mutation (Table 5), and the most common one
(BRAFV600E) can be demonstrated by immunohistochemistry (see also below). Interestingly, a recent
study showed BRAFV600E staining in both MA and epithelial WTs with overlapping features [61].
Additionally, diffuse CD57 staining favors the diagnosis of MA, but does not rule out WT [20], whereas
CK7 negativity of both WTs and MAs distinguishes them from PRCC [17,20].
In general, all other tumors which can show an epithelioid pattern (MRTKs, CCSKs, epithelioid
angiomyolipomas) are negative for WT1 [40]. To further distinguish between these tumors, the panel
of antibodies can be extended (Table 6), for example with PAX8 for the distinction of TFE-tRCCs
from epithelioid angiomyolipomas, since the latter are also positive for melanocytic markers and
angiomyolipomas may also have Xp11 (TFE3-related) translocations (next sections; Table 7).
2.1.3. Genetics
Genetic analysis plays a minor role in the identification of WTs, since >50 driver mutations are
known in WTs (Table 5), but the most commonly mutated genes may be analyzed to exclude other
entities [69]. Interestingly, TRIM28 mutations have been associated with a specific subset of purely
epithelial WTs [70].
Type 1 PRCCs show MET alterations in 81%, and 25% of type 2 PRCCs harbor CDKN2A
genomic abnormalities [71]. MiT-RCCs harbor translocations that lead to fusions with different genes:
Xp11.2 tRCCs harbor translocations of the Transcription Factor E3 (TFE3) gene with different fusion
partners (Table 7), and t(6;11) RCC fuses Transcription Factor EB (TFEB) to MALAT1. Since some
antibodies can be technically challenging and sensitive to suboptimal fixation (e.g., TFE3 and TFEB) [72],
Fluorescent in situ hybridization (FISH) break apart probes detecting the TFE3 [73], TFEB [74], and
ALK translocation [67,75,76] can be used (Table 7), although false negative results have been reported.
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Table 5. The most common genetic aberrations useful in the differential diagnoses of pediatric
renal tumors.
Tumor Type Subtype Genetic Aberrations Useful inDiagnostics Techniques
WT
~35% WT1, CTNNB1, WTX NGS
~10% SIX1/2 NGS
~15% microRNA processing genes
(DROSHA, DGCR8, DICER1) NGS
~ 2.5% TRIM28 mutations (up to 90% in
pure epithelial WT) NGS
~5% TP53 mutations (Anaplastic WT) IHC, NGS
Less common mutations: FXBW7, MYCN,
BCOR, MLLT1 NGS
CCSK
Somatic BCOR-ITD (85-100%) IHC, FISH
t(10;17) (~10%) FISH
Rare: BCOR-CCNB3 translocation FISH, NGS
MRTK ~95% biallelic inactivation INI1 (SMARCB1)~5% SMARCA4 mutations IHC, NGS, NGS
CMN










t(6;11) tRCC Translocations involving TFEB IHC (TFEB), FISH
Xp11.2 tRCC Translocations involving TFE3 IHC (TFE3), FISH
PRCC
Type 1: 81% MET alterations NGS
Type 2: 25% CDKN2A alterations NGS
ALK-RCC Translocations involving ALK FISH
HLRCC-RCC FH mutations IHC, NGS
SDH-related RCC SDHB mutations IHC, NGS
Metanephric
tumors
MA ~90% BRAFV600E mutation IHC, NGS
MST ~65% BRAFV600E mutation IHC, NGS
MAF ~50% BRAFV600E mutation IHC, NGS
Neuroblastoma
Mainly in high risk: MYCN amplification
(18–38%) FISH, NGS
Mutations in a variety of genes (e.g.,
MYCN) NGS
EWS Translocations involving EWS FISH
DSRCT >95% t(11;22)(p13;q11.2 or q12) FISH
WT = Wilms tumor; CCSK = clear cell sarcoma of the kidney; MRTK = malignant rhabdoid tumor of the
kidney; CMN = congenital mesoblastic nephroma; RCC = renal cell carcinoma; tRCC = translocation associated
renal cell carcinoma; ALK-RCC = anaplastic lymphoma kinase-rearranged RCC; HLRCC-RCC = hereditary
leiomyomatosis renal cell carcinoma - RCC; SDH-related -RCC = succinate dehydrogenase related renal cell
carcinoma; MA = metanephric adenoma; MST = metanephric stromal tumor; MAF = metanephric adenofibroma;
EWS = Ewing sarcoma; DSRCT = desmoplastic small blue round cell tumor; IHC = immunohistochemistry;
FISH = fluorescence in situ hybridization; NGS = next generation sequencing; ITD = internal tandem duplication;
ID = internal deletion.
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2.2. Mesenchymal Pattern
2.2.1. Histology
Mesenchymal tumors generally consist of spindle cells arranged in different patterns, such as
short or long bundles, fascicles or storiform architecture. WTs can consist (nearly) completely of
mesenchymal cells (Figure 2), and thorough sampling can help revealing important histologic clues to
the diagnosis of WTs (such as the finding of NRs or small foci of other WT components). CCSK, CMN
and metanephric stromal tumor (MST) are the most important differential diagnostic considerations.
In rare cases, sarcomas (e.g., synovial sarcoma), inflammatory myofibroblastic tumors, and RCCs with
sarcomatous differentiation enter the differential diagnosis.
Histologically, different patterns exist in CCSKs, leading to a substantial number of
misdiagnoses [38]. Nevertheless, approximately 90% of CCSKs show, at least focally, the classic
pattern with bland ovoid cells with monomorphous nuclei with finely dispersed chromatin and
small nucleoli, which are arranged in cords and nests separated by a chicken-wire vasculature
(Figure 2) [13,38].
In very young children, CMN is another important consideration. It encompasses three histologic
variants: classic, cellular, and mixed, containing areas of both cellular and classic histology (Table
S2). The classic type consists of bland spindle cells organized in an interlacing fascicular pattern,
embedded in collagenous stroma blending into the pre-existent renal parenchyma, with entrapment of
normal renal parenchyma. The cellular type has a higher cellularity of ovoid cells with less cytoplasm,
organized in solid sheets, and with a higher proliferation rate, and a rather clear border towards the
renal parenchyma [3].
MST is a rare tumor, which histologically resembles CMN, but occurs at an older age than CMN.
It shows some characteristic histologic features, including alternating cellularity, a scalloped border
with the renal parenchyma, perivascular cuffing, and angiodysplasia (Table S2; Figure 2) [42].
When the most common renal tumors showing a mesenchymal pattern are excluded, some very
rare tumors, such as primary renal sarcomas need to be considered, especially in older children [77].
Interestingly, primary renal synovial sarcomas are usually monophasic [77]. Although, rare in the
kidney, inflammatory myofibroblastic tumor is another diagnostic consideration.
Finally, in teenagers and young adults, sarcomatous dedifferentiation of RCC types (such as clear
cell RCC) is a phenomenon to consider in the differential diagnosis. Interestingly, in these spindle cell
areas, immunoreactivity for markers normally seen in the original tumor type is often lost, whereas
most cases show abnormal p53 immunoreactivity suggestive of a TP53 mutation [78]. Additional
sampling in search for the original tumor type is warranted.
2.2.2. Immunohistochemistry
Although, many renal tumors with a mesenchymal pattern lack a characteristic
immunohistochemical profile (Table 3), a panel of markers can be of added value to differentiate
the tumors (Table 3, Table 6). In the stromal component of WTs, nuclear staining for WT1 is often
weak or absent. CCSKs show a distinctive immunohistochemical profile, with strong CyclinD1, BCL6
corepressor (BCOR), and NGFR staining, and negative WT1 staining (Figure 2; Table 3) [31–34,39].
CMNs have a rather non-specific immunohistochemical pattern (Figure 2; Table 3), although pan-Trk
staining can be used to diagnose cellular CMNs harboring the ETV6-NTRK3 translocation (see
below) [79]. CMNs may show variable CyclinD1 positivity [31,32], and in very rare cases even WT1
positivity [40]. The majority of MSTs are BRAFV600E (~65%) and CD34 positive (Figure 2), while the
other tumors are usually negative [18,35,42,80]. The rare primary renal synovial sarcomas are positive
for CD99, vimentin and TLE1, and often demonstrate at least focal expression of cytokeratins and EMA,
but can be negative or only weakly positive for INI1 [81]. Furthermore, nearly all stromal WTs and
synovial sarcomas show strong BCL-2 staining, whereas approximately half of CCSK and all CMNs
are negative [35].
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Figure 2. The most common pediatric renal tumors with a stromal pattern and their most important
immunohistochemical stainings. The stromal type WT consists of spindle cells, which often shows
more patchy or focal staining for WT-1 and they lack staining for BCL6 corepressor (BCOR). The
classical pattern of a clear cell sarcoma of the kidney (CCSK) has a fine vasculature surrounding
nests of rather monotonous cells (“chicken wire” vasculature), and the characteristic strong nuclear
staining for BCOR as well as CyclinD1. A mixed type congenital mesoblastic nephroma (CMN) with
hypercellular areas resembling the cellular subtype and less cellular areas resembling the classic subtype;
the immunohistochemical pattern is rather indistinct, including lack of staining for WT1 and CyclinD1.
Metanephric stromal tumor (MST), showing the formation of concentric rings of stroma surrounding
some of the epithelial tubules (referred to as “onion skinning”); the stromal component of metanephric
tumors lacks WT1 staining, but stains strongly with CD34. H&E and immunohistochemical stainings
at 10×magnification; inset at 40×magnification.
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Table 6. Recommended immunohistochemical panels in the differential diagnosis of pediatric
renal tumors.
Panels Immunohistochemical StainsRecommended in Panel Additional Stains Which Can be Useful
Epithelial pattern WT1 CK7 PAX8 INI-1
Pan-cytokeratin TFE3 * BCOR * CD10
Melanocytic
markers TFEB * Cathepsin K Vimentin
AMACR BRAFV600E * ALK CyclinD1
2SC/FH
Mesenchymal
pattern WT1 BCL-2 INI1 pan-Trk *
CD34 NGFR * CD99 TLE1 *




markers CD56 BCOR *
INI1 Cyclin D1 CD99 PHOX2B *
Keratins NB84 * CD45
Desmin NGFR *
In bold the most important immunohistochemical stains per pattern which will distinguish the most important
tumors in the differential diagnosis of each pattern; the additional markers can be used as further support for the
differential diagnosis as described in the text and Tables 2–4; * if available.
2.2.3. Genetics
If histologic and immunohistochemical features are insufficient to reach a final diagnosis, molecular
analysis can help in the distinction of some mesenchymal tumors (Tables 5 and 7). As mentioned in
previous sections, many driver genes are involved in WTs (Table 5), which may be included in a targeted
sequencing panel. In CCSKs, ~85% harbor the BCOR-internal tandem duplication (BCOR-ITD) of exon
15, and ~10% show the t(10;17) leading to YWHAE-NUTM2 fusion. These two molecular abnormalities
are mutually exclusive and can be demonstrated by FISH and/or sequencing techniques [82,83]. Rare
CCSKs harbor the BCOR-CCNB3 fusion [39]. The recently reported EGFR-ITDs rearrangements in
all CMN types, together with the previously known t(12;15) (ETV6-NTRK3 translocation) in cellular
CMNs help to confirm the diagnosis of CMN [84,85]. BRAF V600e mutations in MSTs can be identified
by immunohistochemistry or sequencing [86]. A PCR study on 22 CMNs (including 10 cellular
CMNs) showed no BRAF V600e mutations [80]. In one study 2 out of 3 cellular CMN which showed
no ETV6 translocation, showed different rearrangements in the BRAF oncogene on WGS [84]. The
diagnosis of synovial sarcoma can be established by demonstrating the characteristic translocation
t(X;18)(p11.2;q11.2), present in >90% of cases [87].
2.3. Undifferentiated Pattern
2.3.1. Histology
Some pediatric renal tumors have an undifferentiated “small round blue cell” appearance, such as
blastemal WTs, MRTKs, as well as tumors that rarely involve or infiltrate the kidney, such as (poorly
differentiated/undifferentiated) neuroblastoma, desmoplastic small round cell tumor (DSRCT), and
Ewing sarcoma (EWS) (Table S2). In addition, lymphoma should always be considered and excluded.
Other tumors described above (e.g., CCSK) occasionally show an undifferentiated appearance.
The blastemal WT component consists of undifferentiated, small blue round cells with a high
cellularity of round to ovoid cells with a high nuclear–cytoplasmic ratio, and brisk mitotic activity
(Figure 3). Blastema often shows different histologic patterns, such as nodular, trabecular, diffuse, and
serpentine [88].
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Figure 3. The most common pediatric tumors with an undifferentiated pattern and their most important
immunohistochemical stainings. Wilms tumor (WT) with undifferentiated blastema shows strong
nuclear staining for INI1 as well as for WT1. Malignant rhabdoid tumors of the kidney (MRTKs)
often how l rge cells with large eccentric nuclei, characteristic loss of INI1 staining and a sig ificant
percentage of MRTKs do not stain (or only focally) for muscle markers such as desmin. The rare
desmoplastic small round cell tumor (DSRCT), depicted in the third row, highly resembles blastemal
WTs specifically with staining for WT1 (only C-terminal clone; not shown) and MRTKs, but with strong
staining for INI1 and desmin in all cells. Ewing sarcoma shows INI1 staining and strong membranous
CD99. When tumors are large and infiltrate the kidney, tumors such as neuroblastoma (NB) enter the
differential diagnosis. As depicted in the last row, these also show a small blue round cell phenotype,
without loss of INI1, but with strong staining for neuroendocrine markers such as chromogranin A.
H&E and immunohistochemical stainings at 10×magnification; inset at 40×magnification.
Cancers 2020, 12, 729 12 of 20
MRTKs are aggressive infiltrating tumors with a very poor prognosis, often presenting in patients
younger than two years of age [2,15]. They are highly cellular, non-encapsulated tumors composed
of infiltrating sheets of non-cohesive cells with a large eccentric nucleus, and abundant eosinophilic
cytoplasm (Figure 3) (Table S2) [15]. However, MRTKs may show different patterns, which sometimes
lead to difficulties in achieving a correct diagnosis on routine H&E staining only [15].
Neuroblastomas often originate in the adrenal gland, but very rarely in the kidney. Clinically,
most neuroblastomas can be suspected by elevated levels of catecholamines in urine and serum.
Histologically, the nuclei of the undifferentiated cells show the characteristic coarse ‘salt and
pepper’ chromatin. Neuroblastomas lack a pseudocapsule, and often show neuroblasts exhibiting
variable degrees of differentiation up to ganglion cells and neuropil, which is the basis for histologic
classification [89].
DSRCTs have been rarely described in the kidney [90]. Histologically, they consist of solid nests
of round to oval cells and show necrosis and occasional pseudoglandular-/rosette formation [44,91].
Intriguingly, renal DSRCTs show no desmoplasia, making their histologic diagnosis even more
difficult [90].
Primary renal sarcomas rarely occur, and are histologically characterized by undifferentiated
morphology. EWS can originate in the kidney or develop in the retroperitoneum with infiltration of the
kidney [45,92]. These tumors consist of small round to oval cells with scanty cytoplasm, molding, high
mitotic activity, and with condensation around blood vessels [45]. Two newly described sarcomas, very
rarely seen in children in the kidney, are the CIC-DUX4 translocation sarcoma and the BCOR-CCNB3
translocation sarcomas [93]. Both tumors often show a spectrum of round cells to more epithelioid and
spindle cells, often present at least focally [93,94]. The CIC-DUX4 sarcomas behave highly aggressively,
often metastasizing early in the disease course [93,94].
Renal medullary carcinoma (RMC) and collecting duct carcinoma (CDC) may show significant
histologic overlap with MRTKs. Helpful diagnostic clues are the presence of a reticular or cribriform
pattern and finding of sickle cells in RMC [95], while dysplastic changes in the adjacent tubules and a
dense inflammatory infiltrate suggest CDC [95,96].
2.3.2. Immunohistochemistry
The differential diagnosis of “small blue round cell tumors” of the kidney can be difficult, but
most of these tumors can be classified using ancillary techniques (Tables 4 and 5). The blastemal
component of WTs demonstrates nuclear WT1 positivity in 80% of cases [17,46]. DSRCTs are also
WT1 positive [44], but only with the C-terminal clone of WT1, while WTs are positive, with both the
N-terminal and C-terminal clone [40,44,47,48]. DSRCTs also show dotlike cytokeratin and desmin
positivity [16,44]. Blastemal type WTs and neuroblastomas are both positive for CD56, but WT1 is
negative in neuroblastoma [16,40,47], while synaptophysin, chromogranin A, NB84, and PHOX2B are
positive in neuroblastoma [49,53]. Furthermore, WTs are PAX8 positive, while neuroblastoma, DSRCT
and sarcoma are PAX8 negative [34]. MRTKs can be rather easily distinguished from all other pediatric
renal tumors by their complete loss of INI1 staining (Figure 3) and PAX8 negativity.
However, RMCs can also show near complete loss of INI1 immunoreactivity, but are PAX8
positive [16,52,96,97]. In EWS, CD99 (diffuse strong membranous) and cyclinD1 (nuclear), in
combination with lack of reactivity to WT1, discriminates it from WT and almost all other tumors [16,51].
Of note, CIC-DUX4 translocation sarcomas have been reported to show WT1 staining in >90%, while
BCOR-translocation sarcomas were reported to show strong staining of BCOR, BCL-2, cyclinD1, and
TLE1 staining in most cases (each 80–90%) [93,94]. Further differentiation of undifferentiated round
cell sarcomas needs molecular studies (below).
2.3.3. Genetics
In difficult cases, next generation (targeted) sequencing can be performed including genes
frequently mutated or altered in WTs (e.g., WTX, WT1, CTNNB1, SIX1, SIX2, miRNA processing genes)
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and neuroblastomas (PHOXB2, ALK, ARID1A/B genes) (Table 5). Notably, MYCN can show alterations
(mutations as well as gains) in both WT and neuroblastoma [98].
MRTKs are characterized by inactivating mutations in the chromatin-remodeling complex members
INI1 (also referred to as SMARCB1; 95%) or SMARCA4 (5%), or show deletions of 22q11 (on which INI1
is located) [99–101]. Therefore, sequencing of INI1 and SMARCA4 is helpful in establishing a diagnosis
of MRTK. Notably, when patients with a MRTK have a synchronous or metachronous rhabdoid tumor
affecting other organs (including the central nervous system, referred to as Atypical Teratoid/Rhabdoid
Tumor (AT/RT)), it is highly suggestive of the rhabdoid tumor predisposition syndrome [102].
The diagnosis of DSRCT is based on the demonstration of the characteristic t(11;22)(p13;q12)
leading to EWS-WT1 fusion [90]. In contrast, EWS show a wide variety of translocations involving the
EWS gene (Tables 5 and 7), most commonly t(11;22)(q24;q12) resulting in the EWS-FLI1 fusion [45,92].
In EWS-negative round cell sarcomas, CIC-DUX4 gene fusion (resulting from either t(4;19) or t(10;19)),
is the most common genetic abnormality detected [94]. The remainder includes BCOR-CCNB3
translocation sarcomas, harboring the same translocation reported in some CCSKs, suggesting that
they might be in the same spectrum [93,103].
Table 7. Translocations present in the most common pediatric renal tumors which can be demonstrated
by fluorescent in situ hybridization (FISH).
Tumor Type Translocation Fusion FISH Probe
Xp11.2 tRCC





t(6;11) tRCC t(6;11)(p21;q12) TFEB-MALAT1 TFEB break-apart
CCSK
t(10;17)(q22;p13) YWHAE-NUTM2B/E YWHAE or NUTM2break-apart
inv(X)(p11.4;p11.22) BCOR-CCNB3 BCOR-CCNB3 fusion




DSRCT t(11;22)(q13;q12) WT1-EWS EWS break-apart
EWS-rearranged
sarcomas






EWS-negative sarcomas t(4;19) or t(10;19 CIC-DUX4 CIC or DUX4 break-apart
inv(X)(p11.4;p11.22) BCOR-CCNB3 BCOR-CCNB3 fusion
ALK-RCC
t(2;10)(p23;q22) VCL-ALK ALK break-apart
t(1;2)(q25;p23) TPM3-ALK
t(1;2)(p32;p23) HOOK-ALK
FISH = fluorescence in situ hybridization; tRCC = translocation associated renal cell carcinoma; CCSK = clear cell
sarcoma of the kidney; CMN = congenital mesoblastic nephroma; DSRCT = desmoplastic small blue round cell;
EWS = Ewing Sarcoma; ALK-RCC: anaplastic lymphoma kinase-rearranged RCC.
2.4. Biphasic Tumors
In the differential diagnosis of WTs with stromal and epithelial components, Metanephric
adenofibroma (MAF) needs to be considered, despite its rarity. MAFs show features of both MST and
MA (as described above), including positive nuclear staining for WT1 in the epithelial component, and
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positive CD34 staining in the stromal component [104,105]. Furthermore, approximately 50% of MAFs
carry the BRAF V600E mutation, although rare WTs may also harbor a BRAF mutation [18,61,106].
3. Future Perspectives
In addition to Hematoxylin and Eosin (H&E)-based diagnosis, with the aid of
immunohistochemistry and targeted molecular analysis, there are now several developments, which
may revolutionize tumor diagnosis in the near future. First of all, genome-wide molecular methods,
including whole exome sequencing, RNA sequencing, and methylation arrays, allow unprecedented
molecular classification of tumors, as has been shown for brain tumors and renal cell carcinoma [107,108].
While tumor heterogeneity, which is undoubtedly present in Wilms tumors, might be an obstacle
to these genome wide molecular methods, liquid biopsy holds the promise that it would be able to
circumvent this problem, as cell-free DNA in the blood might be representative of the entire tumor [109].
Another strategy, by which pediatric renal tumors might be classified, is based on recent advancements
in the field of radiology, especially the addition of diffusion-weighted imaging to standard magnetic
resonance imaging, with which apparent diffusion coefficient metrics may predict the composition of
renal tumors, especially that of WTs [110]. Finally, through digitalization of traditional H&E slides,
so-called whole slide images can now be analyzed by machine learning techniques. This has already
resulted in automated recognition of specific tissue components, such as lymph node metastases
in breast cancer [7]. It is certainly conceivable that such automated recognition will also lead to
computer-assisted classification of tumor types, including pediatric renal tumors.
4. Conclusions
The differential diagnosis of pediatric renal tumors can be challenging if based solely on H&E
staining, due to the presence of similar cell types and overlapping histologic patterns across these
tumors. Extensive sampling may reveal the presence of distinctive histologic features, allowing a
diagnosis or narrowing the differential diagnosis. However, the use of ancillary techniques is necessary
in many cases. Many ancillary techniques are integrated now in daily pathology practice and provide
the pathologist with tools to achieve the correct diagnosis, which contributes to multidisciplinary
decision-making regarding the appropriate treatment and counselling for each child with a renal
tumor. Since there is a large repertoire of immunostainings and genetic aberrations, the challenge lies
in choosing a restricted panel of ancillary techniques, which results in an appropriate diagnosis in an
acceptable time frame and at an acceptable cost. In this review, we used a pattern-based approach to
discuss the differential diagnosis, and provided recommendations for panels of ancillary techniques.
The focused use of ancillary techniques will likely result in fewer unclassified cases, and lead to an
increase in children diagnosed with germline mutations. This will result in patients benefitting from
receiving adequate therapies and counseling.
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9. Vujanić, G.M.; Gessler, M.; Ooms, A.H.A.G.; Collini, P.; Coulomb-l’Hermine, A.; D’Hooghe, E.; de Krijger, R.R.;
Perotti, D.; Pritchard-Jones, K.; Vokuhl, C.; et al. The UMBRELLA SIOP-RTSG 2016 Wilms Tumour Pathology
and Molecular Biology Protocol. Nat. Rev. Urol. 2018, 15, 693–701. [CrossRef]
10. Jackson, T.J.; Williams, R.D.; Brok, J.; Chowdhury, T.; Ronghe, M.; Powis, M.; Pritchard-Jones, K.; Vujanić, G.M.;
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90. Wang, L.L.; Perlman, E.J.; Vujanić, G.M.; Zuppan, C.; Brundler, M.A.; Cheung, C.R.; Calicchio, M.L.; Dubois, S.;
Cendron, M.; Murata-Collins, J.L.; et al. Desmoplastic Small Round Cell Tumor of the Kidney in Childhood.
Am. J. Surg. Pathol. 2007, 31, 576–584. [CrossRef]
91. Mora, J.; Modak, S.; Cheung, N.K.; Meyers, P.; de Alava, E.; Kushner, B.; Magnan, H.; Tirado, O.M.;
Laquaglia, M.; Ladanyi, M.; et al. Desmoplastic Small Round Cell Tumor 20 Years after Its Discovery. Future
Oncol. 2015, 11, 1071–1081. [CrossRef]
92. Murugan, P.; Rao, P.; Tamboli, P.; Czerniak, B.; Guo, C.C. Primary Ewing Sarcoma/Primitive Neuroectodermal
Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Pathol. Oncol. Res. 2018, 24, 153–159. [CrossRef]
93. Kao, Y.C.; Owosho, A.A.; Sung, Y.S.; Zhang, L.; Fujisawa, Y.; Lee, J.C.; Wexler, L.; Argani, P.; Swanson, D.;
Dickson, B.C.; et al. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of
36 Cases with Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.
Am. J. Surg. Pathol. 2018, 42, 604–615. [CrossRef]
Cancers 2020, 12, 729 20 of 20
94. Antonescu, C.R.; Owosho, A.A.; Zhang, L.; Chen, S.; Deniz, K.; Huryn, J.M.; Kao, Y.C.; Huang, S.C.; Singer, S.;
Tap, W.; et al. Sarcomas with CIC-Rearrangements Are a Distinct Pathologic Entity with Aggressive Outcome:
A Clinicopathologic and Molecular Study of 115 Cases. Am. J. Surg. Pathol. 2017, 41, 941–949. [CrossRef]
[PubMed]
95. Ohe, C.; Smith, S.C.; Sirohi, D.; Divatia, M.; de Peralta-Venturina, M.; Paner, G.P.; Agaimy, A.; Amin, M.B.;
Argani, P.; Chen, Y.B.; et al. Reappraisal of Morphologic Differences between Renal Medullary Carcinoma,
Collecting Duct Carcinoma, and Fumarate Hydratase-Deficient Renal Cell Carcinoma. Am. J. Surg. Pathol.
2018, 42, 279–292. [CrossRef] [PubMed]
96. Gupta, R.; Billis, A.; Shah, R.B.; Moch, H.; Osunkoya, A.O.; Jochum, W.; Hes, O.; Bacchi, C.E.; de
Castro, M.G.; Hansel, D.E.; et al. Carcinoma of the Collecting Ducts of Bellini and Renal Medullary
Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma
with a Focus on Their Interrelationship. Am. J. Surg. Pathol. 2012, 36, 1265–1278. [CrossRef] [PubMed]
97. Seo, A.N.; Yoon, G.; Ro, J.Y. Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and
Related Renal Cell Carcinomas. Adv. Anat. Pathol. 2017, 24, 65–77. [CrossRef] [PubMed]
98. Williams, R.D.; Chagtai, T.; Alcaide-German, M.; Apps, J.; Wegert, J.; Popov, S.; Vujanić, G.; van Tinteren, H.;
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